PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters-Reference-Cited by-同舟云学术

PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters

Published:2007-12-14 Issue:2 Volume:21 Page:131-139
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Catasus Lluis,Gallardo Alberto,Cuatrecasas Miriam,Prat Jaime

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/3800992.pdf

Reference45 articles.

1. American Cancer Society. Cancer Facts and Figures 2007. American Cancer Society: Atlanta, GA, 2007.

2. Prat J . Prognostic parameters of endometrial carcinoma. Hum Pathol 2004;35:649–662.

3. Risinger JI, Berchuck A, Kohler MF, et al. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993;53:5100–5153.

4. Caduff RF, Johnston CM, Svoboda-Newman SM, et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996;148:1671–1678.

5. Catasus L, Machin P, Matias-Guiu X, et al. Microsatellite instability in endometrial carcinomas clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29:1160–1164.

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Rare Pathological Phenotype of Endometrioid Serous and Clear-Cell Ovarian Cancer with PIK3CA Mutations in Relation to The Excellent Response of Alpelisib;Genes;2023-08-16

2. The Role of Genetic Mutations in Mitochondrial-Driven Cancer Growth in Selected Tumors: Breast and Gynecological Malignancies;Life;2023-04-12

3. PIK3CAMutations as a Prognostic Factor in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy;Anticancer Research;2023-03-27

4. PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis;PLOS ONE;2023-03-21

5. Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma;Annals of Medicine;2023-02-11